Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Asset Utilization Ratio (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Asset Utilization Ratio for 13 consecutive years, with 1.43 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Utilization Ratio rose 73.92% year-over-year to 1.43, compared with a TTM value of 1.43 through Dec 2025, up 73.92%, and an annual FY2025 reading of 1.07, up 49.24% over the prior year.
  • Asset Utilization Ratio was 1.43 for Q4 2025 at Karyopharm Therapeutics, up from 1.42 in the prior quarter.
  • Across five years, Asset Utilization Ratio topped out at 1.43 in Q4 2025 and bottomed at 0.36 in Q2 2021.
  • Average Asset Utilization Ratio over 5 years is 0.75, with a median of 0.72 recorded in 2024.
  • The sharpest move saw Asset Utilization Ratio surged 150.56% in 2022, then crashed 49.83% in 2023.
  • Year by year, Asset Utilization Ratio stood at 0.75 in 2021, then decreased by 28.95% to 0.53 in 2022, then rose by 7.36% to 0.57 in 2023, then soared by 43.44% to 0.82 in 2024, then soared by 73.92% to 1.43 in 2025.
  • Business Quant data shows Asset Utilization Ratio for KPTI at 1.43 in Q4 2025, 1.42 in Q3 2025, and 1.18 in Q2 2025.